Pennies 2 Dollars - Investments (P2DI)

[The_Free_Nebula]

TREP meets this criteria in sticky post

[The_Free_Nebula]

TREP - looks powerful...At a critical point of a dime. A bid close over a dime before the next cycle up would be a awesome sign....Should be a really interesting November - P2DI plays climb in powerful stages...

[The_Free_Nebula]

TREP - Has the right fundamentals and sizzle to be a P2DI. The real easy money has been made from double zeros but it still had a second up cycle and looking for a 3rd next week. If the strength continues and the company PRs performance info...A dollar plus is really possible

[Jimmy Quick]

$RXMD NEWS GROWTH AGAIN!
Progressive Care Inc. Announces Month-End Sales Figures Showing Increase in Year-Over-Year Prescriptions Filled in June 2018
Press Release 07/17/2018

MIAMI, July 17, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company, today announced further growth year-over-year in both revenue and number of prescriptions filled for June 2018.
Progressive Care’s wholly owned subsidiary PharmCo, LLC has seen an 18.75% increase in prescriptions filled over the same month last year, totaling approximately 22,500 prescriptions.
June brought a total revenue of roughly $1.65 million in net revenues, a slight decrease from last year in the same month.

WHY THE SIGNIFICANT GROWTH WILL CONTINUE!

[Jimmy Quick]

RXMD Up 30% Today on acquisition completion news.
We are halfway through 2018 and just completed our second location acquisition (TouchPointRX on 7/2/18), and just hired a company 6/27/18 who is feverishly working for the SOLE GOAL of getting us prepared for UPLIST to NASDAQ in first part of 2019. Whatever forces at work will not be able to keep down an over 20 Million NET Revenue producing company from just the 1 location for very long. This will touch .25 again and this will touch .50 prior to NASDAQ uplist.

Today's TouchPointRX acquisition Press Release and 6/27 Benchmark Investment Banking Firm Agreement Press Release is just confirmation of this statement below from CEO Ms. Mars at about the 46 minute mark of 1st quarter call, who is great by the way!
Quarterly Conference Call https://smallcapvoice.com/blog/progressive-care-inc-reports-largest-single-revenue-quarter-in-company-history/

"I want to talk about the future, what our mission is. Why are we growing Pharmco? Why are we growing Progressive Care? Because we are a healthservices company, because we believe we are needed. We are attempting to fill all gaps in a patient's healthcare. That is why we are here, that is why we are growing. TouchPointRX is just the first step in our expansion, we want to go as far as our will will take us. Doing over 20 million in South Florida. We are leading the thought on how healthcare should be. We will grow through acquisitions, and will become a leader in the healthcare space. I understand pessimism, I understand skeptism. But for anybody that doesn't believe you need to get out of our way, because bigger things have tried to take down Progressive Care. Nothing will stop us from becoming what we are destined to be. Nothing will stop us from becoming SEC reporting, nothing will stop us from uplisting to a higher National Exchange. Today is the beginning, and we are on the cusp of more. It doesn't matter what share price is today, the only thing is it won't be there much longer. We will make any investor proud!"

[Jimmy Quick]

$RXMD - RXMD IS ON A COURSE FOR SUCCESS, ON OTCQB and NASDAQ

RXMD BOARD https://investorshub.advfn.com/Progressive-Care-Inc-RXMD-19843/

OUTLOOK FOR 2018: Completion of TWO REVENUE PRODUCING ACQUISTIONS
OUTLOOK FOR 2019: SEC Reporting Compliance, NASDAQ Uplist, and more ACQUISITIONS per CEO Ms. Shital Mars in last quarterly conference call. https://smallcapvoice.com/blog/progressive-care-inc-reports-largest-single-revenue-quarter-in-company-history/

ALL POINTS TO CONTINUED DEVELOPMENT AND GROWTH THROUGH EXPANSION ****INVEST WISELY****

WITH EXTREMELY LOW SHARE STRUCTURE
500 MILLION AUTHORIZED
426 MILLION OUTSTANDING

HERES SOME JUICY 2018 NUMBERS - W/O NEW LOCATION ACQUIRED 3/30/18, these revenues will start to be recognized June 30, 2018
Scripts: 109,600 a 24% increase compared to May 31, 2017
Net Revenue: $8.53 million, a $280,000+ increase compared to May 31, 2017
340B Sales: $2.35 million, a $1.49 million+ increase compared to May 31, 2017
Annualized, 2018 340B Sales are estimated at $6.2 Million, that's nearly a 125% increase of 2017's $2.75 Million.
PharmCoRX is obviously increasing the number of customers.

KEY PHARMACIST COMPENSATION SAVINGS: $473,000 estimated for 2018
Management restructured Key Pharmacist agreement October 1, 2017 to reduce costs, which resulted in a savings of $173,000 compared to last year as recognized in 1st Quarter Results with this F/S Note: During the three months ended March 31, 2018 and 2017, payments to the pharmacist were approximately $87,000 and $260,000, respectively. $87K x 4 = $348 compared to FY 2017 of $821K. This puts us on pace for savings of over $473,000 for 2018


Let’s Take a Very Close Look with the Eyeball on 1st Quarter Results
So we reported $(642,000) Loss.
What really makes up that Loss and Is True Profitability Reflected.
Let’s start from the Net Loss and then dive into the expenses and see what’s really related to Operations.

This completely agrees with F/S information below, which doesn’t take it as far to perform the addbacks to assess RXMD’s true profitability.

For the three months ended March 31, 2018, the Company increased overall revenue from continuing operations to approximately $5.1 million, which resulted in 7% organic revenue growth over the same period in 2017. Gross profit margins decreased from 31% in 2017 to 23% in 2018, an 8% decrease when compared to 2017. Operating income decreased by approximately $390,000 in 2018 as compared to 2017. Annual gross margin in 2018 was negatively impacted by increased DIR fees of approximately $146,000 that the Company records as a component of cost of sales, as well as a decrease in gross margin from the Company’s compounding products. The Company’s net loss for 2018 was negatively impacted by the incremental increase in DIR fees; an amortized charge to operations of approximately $142,000 related to share-based compensation paid to officers, directors and employees; a non-operating loss of approximately $451,000 related to the change in fair value of the derivative liability from the embedded conversion feature in the Chicago Venture Partners note payable; and an increase in personnel associated with the continued growth and development of the Company.

Then let’s observe increase in revenue last year. JUST KEEPS INCREASING YOY

Then check out increase in revenue from the last 2 years.

Overall
G - FY 2013 = $9.3 million
R - FY 2014 = $11.3 million
O - FY 2015 = $13.7 million
W - FY 2016 = $18.3 million (AUDITED)
T - FY 2017 = $20.1 million (AUDITED)
H - FY 2018 = $8.53 million (5 months) does not include 340B revenues


LET'S TALK ABOUT INCOME FROM PREVIOUS YEARS
Shall We . . .
FY 2017 = $49,251 AUDITED Net Income, and w/o Discontinued Operations Net Income is $139,251
FY 2016 = $209,319 AUDITED Net Income, and w/o Discontinued Operations Net Income is $259,319
Yes it did go down by $150,000, but quite explainable with $90,000 from discontinued operations and the information detailed below and still extraordinary when you consider the improvement from 2015 and 2014,
FY 2015 = $(1,219,000) Net Loss
FY 2014 = $(1,009,000) Net Loss

Now let’s analyze where some of expenses effecting additional net income has been applied to development, growth, and expansion initiatives. Growing, Growing, Growing. Everything says they are using money to GROW.


Available Cash Is Building Up !!!
End Of 2017 = $419,000 1st Qtr 2018 = $1,261,000 Million
FY 2017 A/R = $1,270,114 1st Qtr 2018 = $1,128,000
Cash and A/R Combined Cash Assets
December 31, 2017 = $1,689,000
March 31, 2018 = $2,389,000
In awesome position, although a portion will go to acquisition. An increase of over $700K in cash assets and $1.2 million overall in cash assets.

EVERYTHING IS MOVING FORWARDS AND LOOKING GREAT !!!
Another Acquisition Scheduled for 2018
Another Acquisition, SEC Reporting Compliance, and NASDAQ Uplifting for early 2019

SHORT TERM PRICE TARGET $.35

[Jimmy Quick]

$RXMD OVER 20 MILLION NET REVENUES 2017
Just acquired a new second location not included in figures below until after 6/30/2018 finalization of acquisition.

RXMD BOARD https://investorshub.advfn.com/Progressive-Care-Inc-RXMD-19843/

Quarterly Conference Call https://smallcapvoice.com/blog/progressive-care-inc-reports-largest-single-revenue-quarter-in-company-history/

Quick Summary of how RXMD (PharmcoRX) is achieving significant GROWTH RIGHT NOW. Remember 90% of the companies on the OTC don't even have revenues or profits. LOL
RXMD has both and a ton of revenues. Over $20 million net revenues for FY 2018.

[maverick81]

NPHC - HOLDS PATENTED SOLUTION TO THE OPIOID CRISIS




NYLOXIN IS AWAITING DISTRIBUTION ON THE FSS AND GSA ADVANTAGE

The compilation of all these posts will help bring you up to speed To understand the process of getting NYLOXIN distributed to the government. Nyloxin is on the verge of completing the GSA listing process. Here is DD to support this belief

Thanks to BMOC91324 for calling Debra the CEO of EuroAmerican and posting this excellent DD:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139932525
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140061138
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140092902
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140034640


Nutra Pharma Partners with EuroAmerican IP to Distribute Nyloxin® for Sale to Government Agencies


PRESS RELEASE:
https://globenewswire.com/news-release/2018/01/18/1296478/0/en/Nutra-Pharma-Partners-with-EuroAmerican-IP-to-Distribute-Nyloxin-for-Sale-to-Government-Agencies.html


“We are excited to be working with Nutra Pharma,” commented Debra J Paul, CEO, and Tami Dana, COO, of EuroAmerican. “Nyloxin is an exciting alternative to opiate drugs. We believe that it can be a significant tool for combatting opioids in our veterans and in our military,” they continued. “We have seen that Nyloxin substantially reduces all types of pain without mental confusion, addiction or toxicity. We believe that we can quickly and successfully add the Nyloxin products to our existing product list for distribution through our Federal Supply Schedule #V797D-40251 to be available as a replacement for opioids and other pain management drugs” they concluded.


EuroAmerican IP, LLC has been delivering Federal Supply Schedule Commodities to the BOP, DHS, DOJ, DOD, FBI, USCG, HHS, NIH, SSA, VA and other governmental agencies since 2009. Currently offering over 100 contracted items to VA's and OGA's. EAIP is proud to comment that we have only received excellent feedback and appreciation from loyal customers.


Opioid abuse crisis takes heavy toll on US Veterans...

NPHC has a SOLUTION

November 10, 2017

NEW YORK –Opioid drug abuse has killed more Americans than the Iraq, Afghanistan and Vietnam wars combined, and U.S. veterans and advocates this Veteran's Day are focusing on how to help victims of the crisis.

Veterans are twice as likely as non-veterans to die from accidental overdoses of the highly addictive painkillers, a rate that reflects high levels of chronic pain among vets, particularly those who served in the wars in Iraq and Afghanistan, according to federal data.

U.S. government and healthcare officials have been struggling to stem the epidemic of overdoses, which killed more than 64,000 Americans in the 12 months ending last January alone, a 21 percent increase over the previous year, according to the Centers for Disease Control. About 65,000 Americans died in Vietnam, Iraq and Afghanistan.

President Donald Trump named opioids a NATIONAL PUBLIC HEALTH EMERGENCY and a White House commission last week recommended establishing a nationwide system of drug courts and easier access to alternatives to opioids for people in pain.

"Our veterans deserve better than polished sound bites and empty promises," said former Democratic Congressman Patrick Kennedy, a recovering addict and a member of the president's opioid commission.
http://www.foxnews.com/health/2017/11/10/opioid-abuse-crisis-takes-heavy-toll-on-us-veterans.htm


THE TIME IS NOW...
IT IS A NATIONAL CRISIS...
NPHC HAS A REAL VIABLE SOLUTION!!!
AS WE SPEAK ITS IN THE PROCESS OF BECOMING DISTRIBUTED TO THE US GOVERNMENT!!


Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution


PRESS RELEASE:
https://www.nutrapharma.com/single-post/2018/04/19/Nutra-Pharma-Partners-with-NxGen-Brands-for-Nyloxin®-Distribution

“We are pleased to be working with NxGen Brands to expand the marketing of Nyloxin,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Over the past year, we have brought the Nyloxin product line back under our control and have updated our own websites. These efforts to increase internet awareness will continue as we join other marketing groups to greatly expand our reach to educate consumers about Nyloxin and get the product into the hands of those who need it most,” he continued. “We will also be working with NxGen Brands in our capacity as consultants to aid in expanding their in-house product line, improve their manufacturing and look for other synergies for combined growth,” he concluded.

OPENED UP ANOTHER DISTRIBUTION CHANNEL!
MARKETING NYLOXIN TO THE GENERAL POPULATION!
ANOTHER BUILDING BLOCK TO CREATING AWARENESS AND INCREASING SALES!!


Nutra Pharma Announces Nyloxin® Distribution Agreement for Australia and New Zealand


PRESS RELEASE:
https://globenewswire.com/news-release/2018/02/01/1330073/0/en/Nutra-Pharma-Announces-Nyloxin-Distribution-Agreement-for-Australia-and-New-Zealand.html

“We recently announced our domestic efforts to increase sales and distribution of Nyloxin," stated Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "This included the new website, web promotions and our application to be added to the Federal Supply Schedule for sales to US governmental agencies,” he continued. “I'm excited to announce that we have also been working to promote our products internationally. We have been moving forward with our efforts in Canada and India – and we are now announcing our agreement with Pharmachal to be our exclusive distributor of Nyloxin in Australia and New Zealand. Once they receive regulatory approval through the TGA, they will be able to warehouse, market and distribute Nyloxin throughout their territories. We believe this will allow for broad distribution and marketing in that region by the end of this year,” he concluded.

NYLOXIN TO BE DISTRIBUTED AND MARKETED INTERNATIONALLY.
CANADA AND INDIA ARE NEXT...



FACTS ABOUT NYLOXIN Non addictive pain solutions - OPIOID Alternative (FDA Registered)


* Amazon today
* NPHC Controls all patents
* Seeking Nyloxin distributors: Israel, South Africa, Canada, Central and South America
* Currently in 100 pharmacy's and doctors offices
* Working with Military and VA.
* https://nyloxin.com/
* Supported by Jack Brewer.(On Twitter) Executive Chairman & Portfolio Manager of The Brewer Group.
(Very successful investor/financier and has connections with Bio Tech)

Nyloxin is all-natural, anti-inflammatory, analgesic pain relief that is non-toxic, non-narcotic, non-addictive, non-steroidal and does not contain aspirin or acetaminophen !!!

"Nyloxin product is amazing. It’s non-addictive, no opiate, non-narcotic In the last model, it outperformed morphine. It lasted 4-6 hours longer than morphine without any of the side effects. Additionally, since the dose of Nyloxin is so small compared to the dose of morphine required, the Nyloxin was considered to be approximately 600 times more potent than the morphine on a molecular basis,” explained Rik Deitsch, CEO of Nutra Pharma Corp..


"We have also stated that there are no contraindications in utilizing the Nyloxin with opiate drugs. In fact, since their mechanisms of action are so vastly different, we have seen a synergistic benefit. The recommendation is to continue the use of the opiate while introducing Nyloxin to the patient protocol. After a few weeks, most people can reduce their opiate use and many people have even eliminated their use of opiates over time in favor of the Nyloxin". He continued.

NYLOXIN IS A REVOLUTIONARY OPIOID SOLUTION IN MIDST OF A OPIOD REVOLUTION!


ALL THE DD ABOVE demonstrates how there is more going on today than ever!!
NPHC was at 140 million dollar market cap just 3yrs ago with LESS THAN WE HAVE TODAY!!
Let that sink in......... NPHC is way UNDERVALUED here at 5Million dollar MC!
THE MARKET CAP CORRECTION IS COMING...

Mark. it.


Mav

[The_Free_Nebula]

Identifying Criteria for P2DI Opportunities

1. The Stock has to trade reasonable volume daily - relative to its average
2. Increasing revenue stream or better yet profitability. - IOW Reporting
3. A strong product base with expansion potential - consumables a big plus
4. Under 200m O/S - The Revenues/Earnings generated should be taken into account.
5. Insiders have to own shares
6. No dilution to line pockets - must be accretive
7. Previous history of success is important
8. A Prime mover behind it or strong potential for buyout
9. Any Bloated float Stocks (In General) and those with share structures in the Billions are immediately disqualified.

[Shavasana]

$WRFX.
Mick Davis spent 30 years in the department of defense, in the intelligence community, working on Cyber. Counterespionage. Counterterrorism. During his Cybersecurity research he came across the Parano protocol and was so impressed he travelled to Finland to meet the Finns behind it. The technology was so "amazing" as mick states. "I definitely had to stop everything I was doing and come and start working with these guys.”

[OCR8now]

$BMSPF a real pennies to dollars play announces ground breaking this spring on 1 million tonne Bio-Coal plant in Louisiana. Estimate gross rev from 1 million tonnes to be $200 million annually.

http://www.einnews.com/pr_news/442239712/biomass-secure-power-inc-enters-into-a-licensing-agreement

BIOMASSSECUREPOWER.CA

[The_Free_Nebula]

LVVV - Has a good shot to be a successful cannabis company... Each licence to cultivate and distribute will propel this upward.. Got one already

[The_Free_Nebula]

ARYC - A Tech company hinting at becoming fully reporting near term. They tweet like crazy and if half is true it will run hard

[Energy&MJ]

you want a pennies to dollars stock...a future nasdaq company, ticker CPWR! pioneering OTEC/SWAC renewable energy technologies primed to bring energy and water needs to emerging markets

[exec_sum]

$SMPI is Going Viral Starting From This Week!

[Quacker]

BRGO

[The_Free_Nebula]

LXRP made it...still not a bid close over a buck but it hit $1.01

[The_Free_Nebula]

LXRP - may finally fulfill the pennies to dollar run soon...maybe not on this upward cycle

[Inve$tor77]

ENDV is the place to be. The run hasn’t started yet imho . Just getting back to where it belongs.

[The_Free_Nebula]

It would be something at 25 cents. There some who say a buck is not out of the question. All I know I am going on the ENDV ride where it goes....

[Inve$tor77]

ENDV .25 is fine with me

[The_Free_Nebula]

Yes... But still not feeling a buck... Long way to go

[Inve$tor77]

ENDV showing life. .10s plus looks good

[The_Free_Nebula]

Definitely a great call....hoping ENDV, LXRP will follow suit

[FELLER]

OWCP (OTC QB) is tons of upside potential! Lots and lots of DD with easy-to-verify links/sources at OwnTheFloat.com, but I'll provide some basics here.

- First, it shouldn't have dipped to below $0.01 to begin with. More details on the legal action OWCP may take against it's former law firm and/or a finance company is mentioned in November 29th, 2016 8K.

- OWCP began it's 2017 surge because of progress of their Clinical Trials after IRB Approval. Up over 400% at it's peak and will surpass that again.

- Research being done by veteran Cannabis research Doctors in the largest hospital in Israel. Israel, if you didn't know, is the 'Medical Marijuana capital of the WORLD', as talked about in a CNN documentary (called "WEED") with Dr. Sanjay Gupta

- Topical Creme (for Psoriasis and others) will be Market Ready by Q2

- Topical Creme was talked about in a recent 8K as having 'encouraging results' which lead to them expanding the size and scope.

- Then, they added two new Advisory Board members... A lady who has helped companies get FDA approval for the last 20 years and a Dermatologist with 15+ years of experience in R&D of skincare products

- AstraZeneca sold off their "troubled (psoriasis) drug" for $445M in 2015, so with the POSITIVE results of OWCP's... Market Value could certainly correct itself upwards to $500M in the coming MONTHS -- hence, the Lotto Play talk. As of now, sitting around $70M after some consolidation.

- OWCP will likely have more products hit the market in Q3 '17 as they've had other things in the pipeline and in trials/studies.

- Sublingual Tablet was talked about and could have licensing deals in the works -- Smokeless Medical Marijuana product for those who can't or don't want to smoke!

- Multiple Myeloma product in initial studies was showing 100% removal of 'bad cells' in 60% of test subjects. This is a form of cancer with 3% survival. That's pretty huge!

- Other products in the works are for PTSD, Migraines, Fibromyalgia, etc.

- OWCP has 8 US PATENTS!

- OWCP's Advisory Board guy has been speaking at many Industry events and is giving the KEYNOTE at "The Wall Street Conference" in Boca Raton, FL on March 1st.

- OWCP is 1 of 2 DIAMOND sponsors now at that Wall Street Conference.

- March 20th is the date their Topical Creme study should be COMPLETED -- fireworks soon after?

Again, all of this DD featured on www.OwnTheFloat.com with verifiable links to the 8K's and whatever else. Definitely working looking at. Many point to AXIM's recent run of 0.395 to 19.80 in 3 months and think their news that fueled the launch wasn't as good as what we have.

[The_Free_Nebula]

two potential P2DI plays...LXRP (CBD Play) and BMBM a hidden potential financial gem (International)

[The_Free_Nebula]

EXAI - got to follow the bid...bought in at 11 cents...Ask now over 20 cents...Bid yet to get there...

[The_Free_Nebula]

EXAI - Dark horse trading shell. May be going the same way that GREI dead shell to over a buck. Insider(s) buying on open market so it is said. See some of the board posting over past week or so from date of this post for further info......Dip at your own risk..

T

[The_Free_Nebula]

Success....SPRWF hits a buck...abtrue P2DI

[The_Free_Nebula]

GNID death spiral from $7 bucks to low of .006 (briefly- maybe 2 trades) now back to 0.09 cents. Board zealots think circumstances may return it to a buck...

[HighPeaks]

Guys check this out! BBTH news!
It's a long term play. Super undervalued! Low floater-17 mil

bBooth, Inc. (OTCQB: BBTH) Nick Cannon On Board - Projected $49.7 Million Revenue 72% EBITDA Margins

Miami, FL -- September 21, 2016 -- InvestorsHub NewsWire -- EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on bBooth, Inc. (OTCQB: BBTH).

No Toxic Debt

Disruptive Interactive Engagement Technology

$49.7 Million Revenue Projected for 2017

Over 100% year over year growth


BBTH may not be at these levels much longer.

See the Report on bBooth, Inc. (OTCQB: BBTH) at EmergingGrowth.com

http://emerginggrowth.com/bbooth-inc-otcqb-bbth-growth-innovation-next-generation-assertive-advertising-technology/

bBooth, Inc. (OTCQB: BBTH) is new to EmergingGrowth.com. Through the company’s bNotifi technology, bBooth, Inc. (OTCQB: BBTH) is the first company able to deliver direct “push-to-screen,” interactive video messaging and advertising content to mobile and desktop screens world-wide.


You have to see it to believe it.

Download the desktop app: http://www.bbooth.com/products/bnotifi/

bBooth, Inc. (OTCQB: BBTH) also boasts margin efficiency, with projected EBITDA margins near 72%, and no toxic debt on its balance sheet. With its bNotifi product launch just underway, and a full sales-pipeline of high-margin recurring revenue opportunities, the company is well-positioned for a strong 2017, with management forecasting full-year gross revenues of nearly $49.69 million.

“Imagine being able to communicate your message directly to the screens of your customers, distributors, team members, fans, and followers – in a media-rich interactive video format, where the message is delivered by someone who appears to walk right out onto the desktop and mobile screens of your recipients – all without your recipients having to open a web browser or other mobile or desktop program,” - Nick Cannon, bBooth, Inc. (OTCQB: BBTH)’s Chief Strategy Officer.

In our view, bBooth, Inc. (OTCQB: BBTH) is the next generation of direct-to-consumer marketing and advertising. No other company has technology that comes close to bBooth, Inc. (OTCQB: BBTH)’s proprietary bNotifi technology, which combines entertainment and powerful branding, merchandising, and lead generation capabilities. With Nick Cannon as bBooth, Inc. (OTCQB: BBTH)’s Chief Strategy Officer, and Baseball Hall of Famer, Frank Thomas on the company’s Advisory Board, this entertainment technology company carries heavy celebrity firepower that will help it expand further into the entertainment and sports verticals. This all translates to strong earnings growth forecasts. Management is forecasting full-year 2017 gross revenue of $49.7 million, full-year 2018 gross revenue of $143.62 million, and full-year 2019 gross revenue of $282.8 million.


BBTH may not be at these levels much longer.

See the Report on bBooth, Inc. (OTCQB: BBTH) at EmergingGrowth.com

http://emerginggrowth.com/bbooth-inc-otcqb-bbth-growth-innovation-next-generation-assertive-advertising-technology/



About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks. This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. Full details about which can be found in our full disclosure, which can be found here, http://www.emerginggrowth.com/disclosure-2284/. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

CONTACT:

Company: EmergingGrowth.com - http://www.EmergingGrowth.com

Contact Email: [e-mail]

[The_Free_Nebula]

SPRWF going from pennies to dollars....a real weed play

[fink]

I know what you are saying.
The element that saddled this play is gone.
That's Wade. A used shell salesman.
He's running OPMZ with an infused MJ thingy.
He set NHND up with these toxic notes then handed the story off to Nate. Nate is a food innovator and this is his first public show.


Look familiar? I'd stay away from OPMZ unless you are good at catching those falling knives.

[The_Free_Nebula]

BTW - I did nibble in @ dz9...spit out some ballast and bought this...whether it is a penny to dollar remains to be scene. Chronic toxic borrowers seldom change their stripes

[The_Free_Nebula]

reading up on it

[fink]

NHMD great DD

What it is,
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124244381


Where it can go,
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122982051


With sales, this is a BIG Board potential play.
Con Agra is in our network and I'm thinking long term buy out.
Add this to Reddi Whip and spray Pam.

[fink]

NHMD, got a loyal long working NITE down right now on the ASK.
Nite is on auto trump.
He wants the Ask something bad.

Great entry.
Yes it will bring the PPS down, so what? It's about the number of shares one ownes.
Only 300 mm to be had.

[fink]

The story hasn't even started yet.
Toxic notes ran it down then. Those got paid off.
Story begins a week from this comming Monday.
Aug 15th. Could go above a dime to a quarter.
Read the Valuation Stickie.


fWIW, it's on a dip now. Going sideways working weak hands out.
.0085-9 is doable. But not garantees.

I want .33

[The_Free_Nebula]

would have been nice to alert back in May

[fink]

NHMD fits this perfect.
Low float, held tight.

.01 PPS.
10 year Big private label deal 5-10 trading days away.

This has to be on your watch list.
Paid off toxic converting notes that has shorts attached and bashing this simple consumable product with every post. Pull those toxic notes out from under them and really stung.

It's a hilarious effort.

Sticky notes has great DD.
Nothing negative about this play.

Just a heads up before the run.
Thank me later.

And yes I have tons of shares from the converted insult.
Holding for a dime+ and big board uplist.
I think it has a chance.

[The_Free_Nebula]

Yeah never know about these plays....I recently had a dead stock in the port ...victim of many r/s and was sitting at 0.01 for years...it closed at $4.85 ....I still don't know why it woke up...not worth looking..I only had 80 stepped on shares of it...When it moved off the bottom the spread was so large it thought it was a glitch...

[stayfocused]

Happy thanksgiving from across the pond guys

[stayfocused]

Apologies I just wanted to correct something I wrote yesterday, I was getting a little ahead of myself.

Should read: $9.3m Gross (not net) EBITDA slightly negative

I still think this will see multi bucks next year. JMHO

[stayfocused]

Thnx, expecting great things next year!

[The_Free_Nebula]

Interesting....GL

[stayfocused]

The train wreck that was ECIG has been turned upright and is now about to leave the station. Latest Q has $15.4m gross revs and $9.3m net revs with an O/S just north of 70M. Annual revs for 2015 could be $55m+ with 4th qtr revs expected to be +25% over Q3 as organic growth starts hitting the top and bottom line. New management has made huge strides in clearing up the balance sheet and very soon they will be hitting the ground on a major tour to bring in institutional investors now that they've managed to get things back on track.

There are a large number of warrants outstanding but it was made clear that investors want a higher ROI before starting to exercise them but as revs increase the warrants should be integrated fairly seamlessly. Toxic debt has been refinanced as has high interest loans to more favourable conditions. The stock has also been targeted for serious short manipulation but that should be a thing of the past going forward.

I'd like to put forward ECIG as a P2DI as I think this could be multi bucks sometime in 2016.

[The_Free_Nebula]

I think my next P2DI will be WLKR @ .050 Walker Innovation Inc. - Some interesting things...

http://walkerinnovation.com/wp-content/uploads/2015/04/InvestorDeck_2015Q1.pdf

[stayfocused]

Hope you're right

[The_Free_Nebula]

AMDA continues it quest for dollar membership. It should consolidate either late Monday or Tuesday then churn until Thursday then push higher by cob Friday all give or take 1/2 a trading session....I predict a 68-72 cent close Friday....

T

[stayfocused]

Yep, been following it for 3 weeks waiting for further consolidation, oops lol.